S R Marder

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Overview of partial compliance
    Stephen R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 90073, USA
    J Clin Psychiatry 64:3-9. 2003
  2. ncbi request reprint Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study
    Stephen R Marder
    Veteran s Affairs Veteran s Integrated Service Networks 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, California 90073, USA
    Biol Psychiatry 62:1363-70. 2007
  3. doi request reprint Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning
    Karin Foerde
    Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA
    Neuropsychology 22:100-9. 2008
  4. ncbi request reprint Defining and measuring negative symptoms of schizophrenia in clinical trials
    Stephen R Marder
    Semel Institute for Neuroscience at UCLA and VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, USA Electronic address
    Eur Neuropsychopharmacol 24:737-43. 2014
  5. ncbi request reprint Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
    Stephen R Marder
    Semel Institute for Neuroscience at UCLA, Los Angeles, CA, USA VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA Electronic address
    Schizophr Res 150:328-33. 2013
  6. ncbi request reprint Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate
    S R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center and the Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA 90073, USA
    Schizophr Res 53:25-30. 2002
  7. ncbi request reprint Can clinical practice guide a research agenda?
    Stephen R Marder
    VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA
    Schizophr Bull 28:127-9. 2002
  8. doi request reprint Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation
    Stephen R Marder
    Building 210, Room 130, West Los Angeles VA Healthcare Center, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA
    J Clin Psychiatry 71:433-41. 2010
  9. ncbi request reprint Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials
    Stephen R Marder
    Semel Institute of Neuroscience, UCLA, Los Angeles, Calif, USA
    J Clin Psychiatry 68:662-8. 2007
  10. ncbi request reprint Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
    Stephen R Marder
    Department of Psychiatry, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, 90024, Los Angeles, CA, USA
    Schizophr Res 61:123-36. 2003

Research Grants

Detail Information

Publications85

  1. ncbi request reprint Overview of partial compliance
    Stephen R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, 90073, USA
    J Clin Psychiatry 64:3-9. 2003
    ..Strategies for managing partial compliance include the treatment of medication side effects, the education of patients about their illness, and the use of long-acting antipsychotic formulations...
  2. ncbi request reprint Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study
    Stephen R Marder
    Veteran s Affairs Veteran s Integrated Service Networks 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, California 90073, USA
    Biol Psychiatry 62:1363-70. 2007
    ..Paliperidone extended-release tablet (paliperidone ER; Invega, Janssen L.P., Titusville, New Jersey) is an oral psychotropic for schizophrenia treatment...
  3. doi request reprint Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning
    Karin Foerde
    Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA
    Neuropsychology 22:100-9. 2008
    ..In contrast, patients were not impaired at learning on the SRT relative to controls, suggesting that patients with schizophrenia may have dysfunction in a specific corticostriatal subcircuit...
  4. ncbi request reprint Defining and measuring negative symptoms of schizophrenia in clinical trials
    Stephen R Marder
    Semel Institute for Neuroscience at UCLA and VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, USA Electronic address
    Eur Neuropsychopharmacol 24:737-43. 2014
    ....
  5. ncbi request reprint Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
    Stephen R Marder
    Semel Institute for Neuroscience at UCLA, Los Angeles, CA, USA VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, CA, USA Electronic address
    Schizophr Res 150:328-33. 2013
    ..The participants could not reach agreement on whether predominant or prominent negative symptoms should be required for study subjects. ..
  6. ncbi request reprint Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate
    S R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center and the Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA 90073, USA
    Schizophr Res 53:25-30. 2002
    ..With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate...
  7. ncbi request reprint Can clinical practice guide a research agenda?
    Stephen R Marder
    VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA
    Schizophr Bull 28:127-9. 2002
    ..This commentary suggests that these practices can be used to define important research questions...
  8. doi request reprint Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation
    Stephen R Marder
    Building 210, Room 130, West Los Angeles VA Healthcare Center, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA
    J Clin Psychiatry 71:433-41. 2010
    ..Safety data from the first 21 months of olanzapine IM, approved in the United States for the treatment of agitation associated with schizophrenia and bipolar disorder, are presented...
  9. ncbi request reprint Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials
    Stephen R Marder
    Semel Institute of Neuroscience, UCLA, Los Angeles, Calif, USA
    J Clin Psychiatry 68:662-8. 2007
    ..In order to determine whether baseline agitation level influences treatment response, the effects of oral aripiprazole in acute patients with schizophrenia experiencing either higher or lower levels of agitation were examined...
  10. ncbi request reprint Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials
    Stephen R Marder
    Department of Psychiatry, David Geffen School of Medicine at UCLA, 760 Westwood Plaza, 90024, Los Angeles, CA, USA
    Schizophr Res 61:123-36. 2003
    ..Aripiprazole's safety profile may offer benefits in schizophrenia treatment...
  11. ncbi request reprint Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  12. ncbi request reprint Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia
    S R Marder
    West Los Angeles VA Medical Center, CA 90073, USA
    Am J Psychiatry 153:1585-92. 1996
    ....
  13. pmc The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia
    Stephen R Marder
    Semel Institute of Neuroscience, University of California at Los Angeles, Calif, USA
    Dialogues Clin Neurosci 8:109-13. 2006
    ....
  14. ncbi request reprint The Mount Sinai conference on the pharmacotherapy of schizophrenia
    Stephen R Marder
    VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA
    Schizophr Bull 28:5-16. 2002
    ....
  15. ncbi request reprint Drug initiatives to improve cognitive function
    Stephen R Marder
    Semel Institute of Neuroscience and Human Behavior at UCLA and the Mental Illness Research, Education, and Clinical Center MIRECC, West Los Angeles VA Healthcare Center, Los Angeles, CA 90073, USA
    J Clin Psychiatry 67:31-5; discussion 36-42. 2006
    ....
  16. ncbi request reprint Antipsychotic drugs and relapse prevention
    S R Marder
    Psychiatry Service, West Los Angeles Veterans Affairs Medical Center, CA 90073, USA
    Schizophr Res 35:S87-92. 1999
    ..Other potential advantages of the newer drugs over the older drugs include the likelihood that they are more effective against negative and cognitive symptoms of schizophrenia...
  17. ncbi request reprint Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia
    Stephen R Marder
    UCLA Neuropsychiatric Institute and the VISN 22 Mental Illness Research, Education, and Clinical Center, MIRECC 210A, West Los Angeles VA Healthcare Center, Los Angeles, CA 90073, USA
    Schizophr Res 72:5-9. 2004
    ..S. Food and Drug Administration (FDA) to clarify guidelines for the design of clinical trials for cognition enhancing agents; and finally, to assist NIMH in developing its research agenda in this area...
  18. ncbi request reprint Novel antipsychotics: comparison of weight gain liabilities
    D A Wirshing
    Department of Psychiatry, V A Greater Los Angeles Healthcare System, CA 90073, USA
    J Clin Psychiatry 60:358-63. 1999
    ..We hypothesized that the unique pharmacodynamic profiles of these agents would contribute to different amounts and patterns of weight gain...
  19. ncbi request reprint The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies
    Philip G Janicak
    Department of Psychiatry, Rush University Medical Center, Chicago, Illinoise 60612, USA
    J Clin Psychiatry 70:25-35. 2009
    ..To evaluate the efficacy of aripiprazole across a range of symptoms-positive, negative, disorganized thought, depression/anxiety, and hostility-in schizophrenia and schizoaffective disorder...
  20. doi request reprint A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy
    John M Kane
    Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY 11004 1150, USA
    J Clin Psychiatry 70:1348-57. 2009
    ..Combining antipsychotics is common practice in the treatment of schizophrenia. This study investigated aripiprazole adjunctive to risperidone or quetiapine for treating schizophrenia and schizoaffective disorder...
  21. ncbi request reprint Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison
    J M Kane
    Department of Psychiatry, Hillside Hospital, Glen Oaks, NY 11004, USA
    Arch Gen Psychiatry 58:965-72. 2001
    ..Advantages are seen in a broad range of symptoms but do not extend to negative symptoms...
  22. ncbi request reprint Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
    Steven G Potkin
    Brain Imaging Center, University of California, Irvine, 92697, USA
    Arch Gen Psychiatry 60:681-90. 2003
    ..This multicenter trial examined the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective disorder...
  23. ncbi request reprint The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update
    Alexander L Miller
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, MC 7792, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    J Clin Psychiatry 65:500-8. 2004
    ..This article reports the recommendations developed in 2002 and 2003 by a group of experts, clinicians, and administrators...
  24. ncbi request reprint Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes
    Stephen R Marder
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Psychiatry 160:1405-12. 2003
    ..The authors compared symptom outcomes, side effects, and social adjustment in stable schizophrenia outpatients who received 2 years of maintenance treatment with risperidone or haloperidol...
  25. ncbi request reprint The effects of clozapine and risperidone on spatial working memory in schizophrenia
    Susan R McGurk
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, New York, NY 10029, USA
    Am J Psychiatry 162:1013-6. 2005
    ..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia...
  26. ncbi request reprint Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry
    M Aravagiri
    Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, Los Angeles, California 90073, USA
    J Mass Spectrom 35:718-24. 2000
    ..This method is being used for the therapeutic drug monitoring of schizophrenic patients treated with RSP and to study the pharmacokinetics and tissue distribution of RSP and 9-OH-RSP in rats...
  27. ncbi request reprint Neuroleptic plasma levels
    T Van Putten
    Veterans Affairs Medical Center, Los Angeles, CA 90073
    Schizophr Bull 17:197-216. 1991
    ..Antipsychotic plasma levels may be most useful when the distinction between side effects and worsening psychosis is unclear. The utility of high neuroleptic plasma levels in the treatment-resistant patient is unclear...
  28. ncbi request reprint Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat
    M Aravagiri
    Psychopharmacology Unit, University of California at Los Angeles, West Los Angeles VAMC, 90073, USA
    Psychopharmacology (Berl) 139:356-63. 1998
    ..04). The low brain/plasma ratio of high potency RSP and 9-OH-RSP may in part be due to their low lipophilicity, log P = 3.04 and 2.32, respectively, resulting in limited non-specific accumulation in brain tissue...
  29. ncbi request reprint Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations
    Javier Quintana
    West Los Angeles Department of Veterans Affairs Health Care Center and Department of Psychiatry, University of California at Los Angeles, School of Medicine, USA
    Biol Psychiatry 53:12-24. 2003
    ....
  30. ncbi request reprint Clinical guidelines: Dosing and switching strategies for long-acting risperidone
    Stephen R Marder
    VA Greater Los Angeles Health Care System, West Los Angeles Health Center, and the Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, USA
    J Clin Psychiatry 64:41-6. 2003
  31. ncbi request reprint The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone
    Michael F Green
    Veterans Affairs VISN 22 Mental Illness Research Education and Clinical Center, Los Angeles, California, USA
    Biol Psychiatry 51:972-8. 2002
    ..This study examined the neurocognitive effects of low-dose haloperidol compared with risperidone over a 2-year period...
  32. ncbi request reprint Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients
    M Aravagiri
    Psychopharmacology Unit, Room 4 B151H Building 210, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA
    J Pharm Biomed Anal 26:301-11. 2001
    ..The data revealed that the norclozapine and clozapine N-oxide metabolites were present at about 58%+/-14% and 17%+/-6% of clozapine concentrations in plasma, respectively...
  33. ncbi request reprint Remission in schizophrenia: proposed criteria and rationale for consensus
    Nancy C Andreasen
    Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA
    Am J Psychiatry 162:441-9. 2005
    ..These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia...
  34. ncbi request reprint Treatment of agitation in patients with schizophrenia
    Stephen R Marder
    Department of Psychiatry and Biobehavioral Sciences, Mental Illness Research, Education, and Clinical Center, West Los Angeles VA Healthcare Center, Los Angeles, Calif, USA
    J Clin Psychiatry 69:e17. 2008
    ..Treatment selection for the agitated patient with schizophrenia involves weighing factors including, but not limited to, the medication's efficacy, side effects, and formulation, as well as the patient's medical history...
  35. ncbi request reprint The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update
    Troy A Moore
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA
    J Clin Psychiatry 68:1751-62. 2007
    ....
  36. ncbi request reprint Pharmacokinetics and tissue distribution of olanzapine in rats
    M Aravagiri
    Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    Biopharm Drug Dispos 20:369-77. 1999
    ..p. administration. The plasma concentration appears to predict the simultaneous concentration in brain and other tissues. There was no marked localized accumulation of olanzapine in any of the regions of the rat brain...
  37. ncbi request reprint Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
    M F Green
    UCLA Department of Psychiatry and Biobehavioral Sciences 90024 1759, USA
    Am J Psychiatry 154:799-804. 1997
    ....
  38. ncbi request reprint Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness
    Stephen R Marder
    Department of Psychiatry and Biobehavioral Sciences, Mental Illness Research, Education, and Clinical Center MIRECC, West Los Angeles VA Healthcare Center, Los Angeles, CA, USA
    J Clin Psychiatry 67:e03. 2006
    ..By focusing on cognitive impairments and negative symptoms, the functional outcomes of patients with schizophrenia may be improved...
  39. pmc Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial
    Jonathan K Wynn
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA
    Schizophr Res 95:134-42. 2007
    ..The results are discussed in terms of animal models, neural substrates, and treatment implications...
  40. ncbi request reprint A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia
    Joseph M Pierre
    Department of Psychiatry, Veterans Administration Greater Los Angeles Healthcare System, and David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, USA
    J Clin Psychiatry 68:705-10. 2007
    ....
  41. pmc Routine outcomes monitoring to support improving care for schizophrenia: report from the VA Mental Health QUERI
    Alexander S Young
    VA Desert Pacific Mental Illness Research, Education and Clinical Center MIRECC, West Los Angeles VA, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    Community Ment Health J 47:123-35. 2011
    ..There are validated instruments and assessment strategies that are feasible for quality improvement in routine practice...
  42. doi request reprint The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
    Keith H Nuechterlein
    Department of Psychology, UCLA Semel Institute for Neuroscience and Human Behavior, 300 Medical Plaza, Rm 2251, Los Angeles, CA 90095 6968, USA
    Am J Psychiatry 165:203-13. 2008
    ....
  43. pmc Psychosocial treatments to promote functional recovery in schizophrenia
    Robert S Kern
    Veterans Affairs Greater Los Angeles Healthcare System MIRECC 210 A, Building 210, Room 116, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    Schizophr Bull 35:347-61. 2009
    ..Overall, these treatments provide a range of promising approaches to helping patients achieve better outcomes far beyond symptom stabilization...
  44. ncbi request reprint Chronic restlessness with antipsychotics
    Irene M Bratti
    San Diego VA Mental Illness Research, Education, and Clinical Center, CA, USA
    Am J Psychiatry 164:1648-54. 2007
  45. doi request reprint The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
    Robert S Kern
    Department of Psychology, Geffen School of Medicine, University of California, Los Angeles CA 90073, USA
    Am J Psychiatry 165:214-20. 2008
    ..S. community sample with the battery administered as a unit...
  46. ncbi request reprint Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia
    Jin Hun Kim
    Schizophrenia Research Group, Department of Psychiatry, Seoul National Hospital, Seoul, Republic of Korea
    Prog Neuropsychopharmacol Biol Psychiatry 32:984-8. 2008
    ..These findings suggest that clozapine should be considered for the treatment of schizophrenia patients with comorbid AUD. However, due to the limitations of this study, further studies will be required to confirm these findings...
  47. doi request reprint Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study
    Michael F Green
    Semel Institute for Neuroscience and Human Behavior, UCLA, 300 Medical Plaza, Rm 2263, Los Angeles, CA 90095 6968, USA
    Am J Psychiatry 165:221-8. 2008
    ..e., a co-primary) that is considered functionally meaningful. The goal of the current study was to describe steps to evaluate four potential co-primary measures for psychometric properties and validity...
  48. pmc Treatment of schizophrenia negative symptoms: future prospects
    Stephen M Erhart
    UCLA Department of Psychiatry and Biobehavioral Sciences, USA
    Schizophr Bull 32:234-7. 2006
    ..We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments...
  49. ncbi request reprint The effects of novel antipsychotics on glucose and lipid levels
    Donna A Wirshing
    Department of Psychiatry, VA Greater Los Angeles Healthcare System, and University of California at Los Angeles, School of Medicine, 90073, USA
    J Clin Psychiatry 63:856-65. 2002
    ..The goal of this study is to compare the effects of novel antipsychotics clozapine, olanzapine, risperidone, and quetiapine and typical antipsychotics haloperidol and fluphenazine on glucose and lipid levels...
  50. ncbi request reprint Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone
    Manickam Aravagiri
    Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Bldg 210 15, 11301 Wilshire Blvd, Los Angeles, California, USA
    Ther Drug Monit 25:657-64. 2003
    ..The current data support the fact that it is important to measure steady-state levels of total active moiety by analyzing both RSP and 9-OHRSP for plasma drug monitoring...
  51. ncbi request reprint In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia
    Robert P Liberman
    UCLA Department of Psychiatry and Biobehavioral Sciences, UCLA Psych REHAB Program, 300 UCLA Medical Plaza, Ste 2263, Los Angeles, CA 90095
    Psychiatry 65:137-55. 2002
    ..Obstacles to success of IVAST may derive from deficits in personal motivation, family involvement, community support, financial resources, premorbid functioning, and medication compliance...
  52. ncbi request reprint Sexual side effects of novel antipsychotic medications
    Donna A Wirshing
    Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine and VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Schizophr Res 56:25-30. 2002
    ..The novel antipsychotic medications offer a more favorable extrapyramidal side effect profile than conventional agents. It is uncertain that the novel antipsychotics have a benefit in terms of sexual side effects...
  53. ncbi request reprint Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria
    Michael F Green
    Neuropsychiatric Institute, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Biol Psychiatry 56:301-7. 2004
    ..The results from this meeting constitute the initial steps for reaching a consensus cognitive battery for clinical trials in schizophrenia...
  54. ncbi request reprint Anterior cingulate dysfunction during choice anticipation in schizophrenia
    Javier Quintana
    Greater Los Angeles VA Health Care System and VA VISN22 Mental Illness, Research, Education and Clinical Center, Los Angeles, CA 90073, USA
    Psychiatry Res 132:117-30. 2004
    ..These results reveal an ACGC dysfunction during choice anticipation in schizophrenia and suggest that it might underlie the foresight deficits seen in schizophrenic patients...
  55. ncbi request reprint Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia
    Shirley M Glynn
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles and Veteran Affairs Greater Los Angeles Healthcare System, 90073, USA
    Am J Psychiatry 159:829-37. 2002
    ....
  56. ncbi request reprint Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats
    Manickam Aravagiri
    Psychopharmacology Unit, University of California at Los Angeles, VA Greater Los Angeles Healthcare System, Building 210, 15, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
    Psychopharmacology (Berl) 159:424-31. 2002
    ....
  57. ncbi request reprint Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients
    Manickam Aravagiri
    Veterans Administration Greater Los Angeles Healthcare System, UCLA, Los Angeles, CA, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 847:237-44. 2007
    ..The data showed large inter-individual variations...
  58. ncbi request reprint Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry
    Stephen M Erhart
    Department of Veterans Affairs Health Care Center Greater Los Angeles, Los Angeles, CA, USA
    J Clin Psychiatry 66:968-73. 2005
    ..We identified the most common signs and symptoms prompting MRIs to establish the predictive value of these signs and symptoms for clinically pertinent organic syndromes...
  59. ncbi request reprint Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms
    T A Mellman
    Department of Psychiatry, Dartmouth Medical School, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Psychiatr Serv 52:619-25. 2001
    ....
  60. ncbi request reprint Better pharmacotherapy for schizophrenia: what does the future hold?
    Michael A Webber
    Semel Institute for Neuroscience at UCLA, Mental Illness Research, Education, and Clinical Center, VA West Los Angeles Health Care Center, MIRECC 210A, 11301 Wilshire Boulevard, Los Angeles, CA 90073 1003, USA
    Curr Psychiatry Rep 10:352-8. 2008
    ..The goal of this future pharmacotherapy strategy is to advance outcomes beyond psychosis remission and toward functional recovery...
  61. ncbi request reprint A review of agitation in mental illness: treatment guidelines and current therapies
    Stephen R Marder
    Department of Psychiatry, David Geffen School of Medicine at the University of California Los Angeles, VISN 22 Mental Illness Research, Education, and Clinical Center, Los Angeles, Calif, USA
    J Clin Psychiatry 67:13-21. 2006
    ..Agitation is an important therapeutic target in the acute and/or emergent setting, as well as for longer-term care of patients with psychiatric illness...
  62. ncbi request reprint MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects
    G Bartzokis
    North Little Rock VA Medical Center, Department of Psychiatry, University of Arkansas for Medical Sciences, 72114, USA
    Magn Reson Imaging 17:213-22. 1999
    ..The FDRI results suggest that disregulation of iron metabolism occurs in PD and that this disregulation may differ in earlier- versus later-onset PD...
  63. ncbi request reprint Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia
    Javier Quintana
    West Los Angeles VA Health Care Center, and Department of Psychiatry, School of Medicine, University of California at Los Angeles, Los Angeles, California 90024 1759, USA
    Biol Psychiatry 53:1099-112. 2003
    ....
  64. ncbi request reprint A compensatory mirror cortical mechanism for facial affect processing in schizophrenia
    J Quintana
    West Los Angeles VA HCC, School of Medicine, University of California at Los Angeles, Los Angeles, CA 90024, USA
    Neuropsychopharmacology 25:915-24. 2001
    ..We found that, when the task cues were facial expressions in contrast to color circles, the schizophrenic group exhibited increased activation of the face movement areas in motor and pre-motor cortex...
  65. pmc Methodological issues in negative symptom trials
    Stephen R Marder
    The Semel Institute for Neuroscience at University of California, Los Angeles, CA
    Schizophr Bull 37:250-4. 2011
    ....
  66. ncbi request reprint Bipolar I disorder: psychopathology, medical management and dental implications
    Arthur H Friedlander
    West Valley Los Angeles County Department of Health, Van Nuys, Calif, USA
    J Am Dent Assoc 133:1209-17. 2002
    ..The authors review the clinical features, epidemiology, pathophysiology, medical management, dental findings and dental management of patients who have bipolar I disorder, or BD, previously known as manic-depressive disorder...
  67. ncbi request reprint Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia
    Baojin Zhu
    Eli Lilly and Company, Lilly Corporate Center Drop 4133, Indianapolis, IN 46285, USA
    Psychiatr Serv 59:315-7. 2008
    ..This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia...
  68. ncbi request reprint Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia
    Daniel S Umbricht
    Department of Psychiatric Research, Psychiatric University Hospital, Zurich, Switzerland
    J Clin Psychiatry 63:420-4. 2002
    ..Clinicians would be well served if clinical characteristics could be identified that predict a favorable response to clozapine. A few studies addressing this issue have reported inconsistent results...
  69. doi request reprint Sex, race, and smoking impact olanzapine exposure
    Kristin L Bigos
    Department of Pharmaceutical Sciences, University of Pittsburgh, School of Pharmacy, 805 Salk Hall, 3501 Terrace St, Pittsburgh, PA 15261, USA
    J Clin Pharmacol 48:157-65. 2008
    ..0001). Differences in olanzapine exposure due to sex, race, and smoking may account for some of the variability in response to olanzapine...
  70. ncbi request reprint Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning
    Marco C G Merlo
    Hĵpitaux Universitaires de Genève, Departement de Psychiatrie, Chene Bourg, Switzerland
    J Clin Psychiatry 63:885-91. 2002
    ..The aim of this study was to examine differences in the improvement of clinical psychopathology and in fine motor functions at 2 doses of risperidone in first-episode, acutely psychotic patients...
  71. ncbi request reprint Olanzapine treatment for patients with schizophrenia and cocaine abuse
    John Tsuang
    J Clin Psychiatry 63:1180 -1. 2002
  72. ncbi request reprint Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 101 Quarry Road 2122, Stanford, CA 94305, USA
    J Clin Psychiatry 66:638-41. 2005
    ..To compare the long-term efficacy and tolerability of oral quetiapine with those of intramuscular haloperidol...
  73. ncbi request reprint Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy
    Lawrence J Albers
    VA Long Beach Healthcare System, Department of Psychiatry and Human Behavior, College of Medicine, University of California Irvine, CA 90822, USA
    J Clin Psychopharmacol 25:170-4. 2005
    ..05). In conclusion, this prospective pilot study suggests that a 26% reduction in olanzapine therapeutic dose requirement may be achieved by coadministration of a nontherapeutic oral dose of fluvoxamine...
  74. ncbi request reprint Social cognition in schizophrenia: relationships with neurocognition and negative symptoms
    Mark J Sergi
    Department of Psychology, California State University at Northridge, Northridge, CA 91330 8255, USA
    Schizophr Res 90:316-24. 2007
    ..The current findings start to provide insights into the structure of social cognition, neurocognition, and negative symptoms in schizophrenia...
  75. ncbi request reprint Switch or stay?
    John M Davis
    Am J Psychiatry 163:2032-3. 2006
  76. ncbi request reprint Lessons from each drug trial
    Stephen R Marder
    Am J Psychiatry 164:375-6. 2007
  77. ncbi request reprint Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia
    Lizheng Shi
    Department of Health Systems Management, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal St, Suite 1900, New Orleans, LA 70112, USA
    Psychiatr Serv 58:482-8. 2007
    ....
  78. ncbi request reprint The heterogeneity of schizophrenia in disease states
    Penny E Mohr
    Centers for Medicare and Medicaid Services, ORDI REG DBR, Mail stop C3 19 07 7500, Security Boulevard, Baltimore, MD 21244, USA
    Schizophr Res 71:83-95. 2004
    ....
  79. ncbi request reprint Do clozapine and risperidone affect social competence and problem solving?
    Alan S Bellack
    Mental Health Research, Education and Clinical Center, VA Maryland Health Care System, Baltimore 21201, USA
    Am J Psychiatry 161:364-7. 2004
    ..The purpose of this investigation was to evaluate the effects of clozapine and risperidone on social skill and problem solving in patients with schizophrenia...
  80. pmc New paradigms for treatment development
    Ellen L Stover
    National Institute of Mental Health, Bethesda, MD, USA
    Schizophr Bull 33:1093-9. 2007
    ....
  81. ncbi request reprint Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol
    Mark J Sergi
    Department of Psychology, California State University, 18111 Nordhoff St, Northridge, CA 91330 8255, USA
    Am J Psychiatry 164:1585-92. 2007
    ..This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition...
  82. ncbi request reprint Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative
    Stephen R Marder
    Am J Psychiatry 161:25. 2004
  83. pmc The NIMH-MATRICS consensus statement on negative symptoms
    Brian Kirkpatrick
    Department of Psychiatry and Health Behavior, Medical College of Georgia, USA
    Schizophr Bull 32:214-9. 2006
  84. ncbi request reprint Newer antipsychotics and the differences between clinical experiences and clinical trials. Interview by Norman Sussman, MD
    Stephen R Marder
    CNS Spectr 12:812-5. 2007
  85. ncbi request reprint The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
    Robert W Buchanan
    Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    Am J Psychiatry 164:1593-602. 2007
    ..Agents that act at the glycine site of the N-methyl-D-aspartic acid (NMDA) glutamatergic receptor have been suggested as promising treatments for moderate to severe negative symptoms and cognitive impairments...

Research Grants19

  1. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    Stephen Marder; Fiscal Year: 2003
    ..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
  2. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2003
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  3. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2002
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  4. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    Stephen Marder; Fiscal Year: 2002
    ..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
  5. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2001
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  6. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    Stephen Marder; Fiscal Year: 2001
    ..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
  7. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2000
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  8. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    Stephen Marder; Fiscal Year: 2000
    ..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
  9. MANAGEMENT OF RISK FOR RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 1990
  10. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 1993
    ....
  11. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2004
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..